Elastomeric Infusion Pumps

Global Elastomeric Infusion Pumps Market to Reach US$910.2 Million by 2030

The global market for Elastomeric Infusion Pumps estimated at US$659.5 Million in the year 2024, is expected to reach US$910.2 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Continuous Rate Elastomeric Infusion Pumps, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$523.9 Million by the end of the analysis period. Growth in the Variable Rate Elastomeric Infusion Pumps segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$179.7 Million While China is Forecast to Grow at 8.5% CAGR

The Elastomeric Infusion Pumps market in the U.S. is estimated at US$179.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$181.0 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Elastomeric Infusion Pumps Market – Key Trends & Drivers Summarized

Why Are Elastomeric Infusion Pumps Gaining Traction in Modern Healthcare Delivery?

Elastomeric infusion pumps are increasingly being embraced across healthcare systems due to their simplicity, portability, and cost-effectiveness in delivering continuous, controlled drug infusions. These non-electric, balloon-like devices use the pressure of an elastomeric reservoir to administer a steady flow of medication over time, eliminating the need for complex electronic programming or external power sources. They are widely used in postoperative pain management, chemotherapy, antibiotic therapy, and palliative care, especially in ambulatory and home-based settings. With healthcare delivery shifting toward outpatient and home-care models, elastomeric pumps are enabling care continuity while reducing the burden on hospital resources. Their lightweight, silent operation and user-friendly design make them ideal for both patient and caregiver use, promoting comfort and compliance without clinical supervision.

As hospital beds become costlier and demand for healthcare services grows, the healthcare industry is prioritizing treatment models that allow patients to recover or manage chronic conditions outside of clinical environments. Elastomeric pumps fit seamlessly into this paradigm, offering clinicians a safe, reliable solution for delivering a consistent dosage over several hours or days. Unlike electronic infusion systems, they require no maintenance or monitoring, reducing the risk of user error and equipment failure. Their single-use design also minimizes contamination risks and cross-patient exposure—crucial in infection-sensitive scenarios such as oncology and post-surgical recovery. These inherent advantages are positioning elastomeric infusion pumps as vital enablers of decentralized healthcare delivery, particularly in low-resource or mobility-restricted settings.

How Are Clinical Needs and Patient Preferences Driving Product Evolution?

The evolving needs of patients and clinicians are significantly shaping the design, functionality, and market expansion of elastomeric infusion pumps. With growing emphasis on patient-centric care, these pumps are being refined to improve ease of use, safety, and comfort. Medical device manufacturers are introducing variants with adjustable flow rates, tamper-proof features, and clear dosage indicators to enhance user confidence and accuracy. For clinicians, the ability to administer medications without constant electronic monitoring or programming reduces workload and allows for more efficient patient throughput. In turn, patients benefit from discreet, wearable pumps that don’t interrupt daily routines or require hospital stays—factors that are especially important in home-based chemotherapy, pain relief, and long-term antibiotic regimens.

The increasing use of elastomeric pumps in pediatric, geriatric, and palliative care has also prompted design improvements focused on minimizing anxiety and maximizing comfort. Materials are being upgraded to be softer, more transparent, and hypoallergenic, while packaging is being redesigned for intuitive handling. Furthermore, the shift toward self-administration and patient empowerment is encouraging manufacturers to simplify instruction protocols and add color-coded or pre-labeled options. In parallel, the growing role of outpatient infusion centers and specialty pharmacies is expanding the distribution of these pumps beyond hospital systems. As demand grows for low-complexity, high-reliability infusion technologies, elastomeric pumps are transitioning from niche tools into standard components of modern drug delivery strategies.

Who Are the Stakeholders and Innovators Leading Market Expansion?

The global elastomeric infusion pump market is being driven by a diverse ecosystem of stakeholders including medical device manufacturers, pharmaceutical companies, home healthcare providers, and regulatory authorities. Leading producers such as Baxter International, Avanos Medical, B. Braun, Terumo Corporation, and Nipro Corporation are at the forefront of innovation, focusing on product customization, improved materials, and broader clinical indications. These companies are partnering with hospitals and specialty clinics to co-develop treatment-specific pump models that align with current dosing protocols in oncology, orthopedics, and infectious disease management. Additionally, drug developers are working closely with device makers to ensure formulation compatibility and stability during continuous infusion—a key requirement in chemotherapy and biologics delivery.

Regulatory agencies such as the FDA and EMA are playing an instrumental role in validating the safety and effectiveness of elastomeric pumps across various therapies, providing the clinical backing necessary for broader insurance coverage and procurement. Home healthcare providers and infusion therapy companies are also influencing adoption by incorporating elastomeric pumps into bundled service offerings that allow patients to transition from inpatient to outpatient care smoothly. Meanwhile, public and private payers are recognizing the cost savings associated with reduced hospitalization and are increasingly reimbursing elastomeric pump use across multiple care settings. As healthcare systems worldwide evolve toward decentralized, cost-efficient care models, this collaborative, multi-stakeholder environment is propelling the market forward and encouraging continuous development in elastomeric infusion pump technologies.

What Factors Are Fueling the Growth Trajectory of the Elastomeric Infusion Pumps Market?

The growth in the elastomeric infusion pumps market is driven by several factors directly linked to technology upgrades, therapeutic use-case expansion, and evolving healthcare delivery models. Technological advancements in elastomeric materials, flow regulator precision, and leak-proof connectors have significantly improved product reliability, safety, and drug compatibility, making these pumps a preferred alternative to electronic devices in specific therapeutic contexts. In terms of end-use, the rising demand for home-based treatments—especially for pain management, oncology care, and post-surgical recovery—is creating consistent and growing demand for portable, non-electric infusion devices.

Consumer behavior is also playing a key role, as patients increasingly seek healthcare solutions that offer autonomy, mobility, and minimal disruption to their daily lives. Hospitals and clinics are responding by expanding ambulatory care services and incorporating elastomeric pumps into ER discharge kits, orthopedic recovery plans, and at-home infusion protocols. Additionally, public and private insurers are recognizing the economic value of elastomeric pumps in reducing inpatient costs and lowering the risk of infusion-related complications. Geographic expansion is another growth driver, with emerging markets investing in decentralized healthcare infrastructure and adopting elastomeric pumps for cost-effective chronic disease management. Furthermore, improved logistics and supply chain distribution—particularly through e-commerce and specialty pharmacy channels—are making these devices more accessible across remote and underserved areas. Together, these technology, clinical, behavioral, and economic factors are fueling robust growth in the global elastomeric infusion pumps market.

SCOPE OF STUDY:

The report analyzes the Elastomeric Infusion Pumps market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Continuous Rate Elastomeric Infusion Pumps, Variable Rate Elastomeric Infusion Pumps); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses); Application (Pain Management Application, Chemotherapy Application, Antibiotic / Antiviral Therapy Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• ACE Medical Co., Ltd.
• Ambu A/S
• Avanos Medical, Inc.
• B. Braun Melsungen AG
• Baxter International Inc.
• Daiken Medical Co., Ltd.
• Epic Medical Pte Ltd
• Fresenius Kabi AG
• Grifols, S.A.
• Halyard Health, Inc.
• Heka s.r.l.
• Leventon, S.A.U.
• Nipro Corporation
• Palex Medical SA
• Progressive Medical, Inc.
• S&S Med
• Smiths Medical (Part of Smiths Group plc)
• Terumo Corporation
• Vygon Group
• Woo Young Medical Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.